ATRN-119 + Decitabine for Acute Myeloid Leukemia and Myelodysplastic Syndrome

This trial explores a new treatment for individuals with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS), particularly those with a TP53 gene mutation. In its early stages (Phase 1), the study aims to determine the safety and tolerability of combining two drugs, ATRN-119 (an experimental treatment) and decitabine. Initially, the trial will test different doses to assess patient reactions, then concentrate on those with a specific genetic change in their AML or HR-MDS. Eligible participants include those diagnosed with AML or HR-MDS who have not responded to previous treatments or are newly diagnosed but unable to undergo intensive chemotherapy. As a Phase 1 trial, this research seeks to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial does not specify if you need to stop taking your current medications, but you cannot take strong inhibitors or inducers of CYP3A4 without a washout period (time without taking these medications) of 5 half-lives or 28 days, whichever is shorter.

Research has shown that decitabine, one of the drugs in this trial, works well and is generally safe for older patients with acute myeloid leukemia (AML). Most patients using decitabine experience manageable side effects, indicating its safety for many people. However, less information exists about ATRN-119, the other drug in this trial, because this is an early-phase study. Researchers are still learning about its safety and tolerability. In these early trials, the main goal is to ensure the treatment does not cause serious harm. Although detailed data on ATRN-119 is not yet available, researchers are closely monitoring its combination with decitabine to ensure patient safety.¹²³⁴⁵

Researchers are excited about ATRN-119 combined with decitabine for treating acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) because it introduces a novel approach to therapy. Unlike traditional chemotherapy, which targets rapidly dividing cells indiscriminately, ATRN-119 focuses on specific molecular pathways involved in the progression of these blood cancers. This targeted approach could potentially lead to more effective treatments with fewer side effects. Additionally, the combination with decitabine, a DNA methylation inhibitor, enhances the treatment's ability to disrupt cancer cell growth and survival. This dual-action strategy offers hope for improved outcomes in patients who may not respond well to existing therapies.

Research has shown that decitabine effectively treats high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It improves patient response to treatment and can increase survival rates. One study demonstrated that combining decitabine with other drugs led to significantly better outcomes, including higher response and remission rates. In this trial, researchers are testing ATRN-119 in combination with decitabine to determine if it can enhance treatment effectiveness. The hypothesis is that ATRN-119 might help decitabine target cancer cells more effectively, particularly in patients with TP53 mutations.¹²⁴⁶⁷